secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silo Pharma, Inc. (SILO)
CIK:        0001514183
Form:       8-K
Filed at:   2023-12-04T23:59:59+00:00
Accession:  0001213900-23-092761
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Silo Pharma shareholders approve 80% authorized share reduction and equity plan at annual meeting
--------------------------------------------------------------------------------

- Four directors elected: Weisblum, Linsley, Muñoz, Pavell (1.45M-1.45M for each).
- Amended 2020 Omnibus Equity Incentive Plan approved (1.43M for, 97,553 against, 11,988 abstain).
- Authorized common shares reduced from 500M to 100M (1.52M for, 2,648 against, 10,000 abstain).
- Ratification of Salberg & Company as auditor approved (1.51M for, 189 against, 66,435 abstain).
- Vote on reincorporation to Nevada adjourned to December 11, 2023; results to be filed later.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514183/000121390023092761/0001213900-23-092761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514183/000121390023092761/ea189483-8k_silo.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-092761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer